Rémy Largillier

Carboplatin-based doublet plus bevacizumab beyond progression versus carboplatin-based doublet alone in patients with platinum-sensitive ovarian cancer: a randomised, phase 3 trial

Sandro Pignata, Domenica Lorusso, Florence Joly et al. · The Lancet Oncology · 2021 · 144 citations

Carboplatin-based Doublet, Medicine, Metronomic Therapy +7

Outcome and prognostic factors in breast sarcoma: A multicenter study from the rare cancer network

Guilhem Bousquet, C Confavreux, Nicolas Magné et al. · Radiotherapy and Oncology · 2007 · 135 citations

Prognostic Factors, Surgical Oncology, Rare Cancer Network +10

Multicenter Phase II Trial of Neoadjuvant Therapy With Trastuzumab, Docetaxel, and Carboplatin for Human Epidermal Growth Factor Receptor-2–Overexpressing Stage II or III Breast Cancer: Results of the GETN(A)-1 Trial

Bruno Coudert, Rémy Largillier, Laurent Arnould et al. · Journal of Clinical Oncology · 2007 · 132 citations · Full text

Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE)

Thomas Bachelot, Eva Ciruelos, Fabio Puglisi et al. · Annals of Oncology · 2019 · 111 citations · Full text

Metastatic Breast Cancer, Breast Oncology, Medicine +7

Pharmacogenetics of Capecitabine in Advanced Breast Cancer Patients

Rémy Largillier, Marie-Christine Étienne-Grimaldi, Jean–Louis Formento et al. · Clinical Cancer Research · 2006 · 102 citations · Full text